Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$26.26 0.49 (1.90%)
2/9/2010 4:00 PM

Regeneron Pharmaceuticals, Inc. (REGN)

CAPS Rating:
**

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating REGN

Add Stock to Watchlist

What the Community Thinks

Total Members

94 Outperforms
31 Underperforms
 

All-Stars

20 Outperforms
15 Underperforms
 

Wall Street

9 Outperforms
1 Underperforms
 

Members bullish on REGN are also bullish on:

Members bearish on REGN are also bearish on:

Ticker Tags

Defensive (1457), Small Cap (1645), Growth (1902), Healthcare (711), Biotechnology (220), Aggressive Growth (860)
Suggest a tag

Regeneron Pharmaceuticals, Inc. At A Glance

Current Price: $26.26
Last Trade Time: 2/9/2010 4:00 PM
Open: $26.15
Previous Close: $25.77
Daily Range: $25.80 - $26.73
52-Week Range: $11.81 - $28.66
Volume: 440,040
Market Cap: $2.11B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

REGN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

Regeneron Pharmaceuticals, Inc. (REGN)

Avatar daviddai (66.36) Submitted: 3/08/07 12:26 PM

The stock has strong therapeutic candidates (interleukin-1 trap and VEGF trap) which, I believe, are likely be approved by FDA in the coming years. This will give them the profit margin that they so desperate need in order to expand their R&D for more drug discovery. They also have very strong R&D...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Regeneron Pharmaceuticals, Inc. (REGN)

Avatar kurthauer1998 (74.16) Submitted: 1/21/08 4:41 PM

The company's clinical development programs include Interleukin-1 (IL-1) Trap for various inflammatory indications, VEGF Trap for oncology, and VEGF Trap-Eye formulation for eye diseases. The IL-1 Trap is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its i...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 17 :   1 2 3 4 Next »

Recs

0

 (REGN)

Avatar gangsterchen (< 20) Submitted: 2/01/10 10:06 PM : Outperform Start Price: $26.50 REGN Score: 0.96

deep pipeline, large pharma partnership, low cash burning rate

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar biacore (< 20) Submitted: 1/25/10 6:11 PM : Outperform Start Price: $26.10 REGN Score: 2.55

Very strong pipeline, with some exciting results due out at the end of this year.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar zzlangerhans (99.64) Submitted: 12/29/09 3:10 PM : Underperform Start Price: $24.27 REGN Score: -13.12

Expansion of the collaboration with Sanofi to receive 160M per year through 2017? Great!

Four phase III trials of Arcalyst in gout in progress with initial data expected in H1 2010? Awesome!

Three phase III trials of aflibercept in metastatic cancer with interim data expected in H2 2010? Super!

Two phase III studies of VEGF Trap-Eye in wet AMD fully enrolled with data expected in H1 2010? Outstanding!

A 60% rise from recent lows, close to a five year high, and 2 billion market cap? Too much!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar Julio60 (< 20) Submitted: 10/05/09 3:31 PM : Outperform Start Price: $18.57 REGN Score: 38.46

bullish

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar mjan706 (< 20) Submitted: 9/22/08 1:44 AM : Outperform Start Price: $22.84 REGN Score: 26.68

An Icahn portfolio stock.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 17 :   1 2 3 4 Next »

Wall Street

Results 1 - 10 of 10  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRothCapital 80.39 01/07/10 Outperform NS $24.90+5.46%-5.53%+10.99
TrackThinkEquity 64.82 05/05/09 Outperform NS $15.03+74.72%+19.63%+55.09
TrackCreditSuiss 93.62 05/01/09 Outperform NS $14.20+84.93%+23.90%+61.03
TrackPiperJaff 85.79 03/30/09 Outperform NS $14.80+77.43%+35.76%+41.68
TrackMerriman < 20 10/24/08 Outperform NS $16.69+57.34%+30.66%+26.68
TrackCanaccord 86.15 11/02/07 Outperform NS $21.19+23.93%-25.18%+49.11
TrackIcahn 32.10 09/30/07 Outperform NS $17.80+47.53%-26.38%+73.90 Toggle the visibility of 60-Second Pitch and replies
TrackNeedham 67.64 11/08/06 Outperform NS $23.95+9.65%-17.39%+27.03
TrackLehmanBros 85.06 10/19/06 Outperform NS $19.50+34.67%-16.53%+51.20
TrackJimCramer < 20 08/16/06 Underperform 3W $14.86+76.72%-12.30%-89.02

Results 1 - 10 of 10  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD03 687ms